Texas is currently home to 4894 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Recruiting
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Relapsed or Refractory T Cell Lymphoma
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Houston Methodist Research Institute (HMRI), Houston, Texas
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Recruiting
The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy with concurrent chemotherapy for the treatment of patients with esophageal adenocarcinoma. NBTXR3 is a drug that when activated by radiation therapy, may cause targeted destruction of cancer cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as oxaliplatin, fluorouracil, capecitabine, doceta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Gastroesophageal Junction Adenocarcinoma, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Thoracic Esophagus Adenocarcinoma
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Recruiting
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a toxic agent called DT. IL-3 attaches to IL-3 receptors on tumor cells in a targeted way and delivers DT to kill them. Drugs used in chemotherapy work in different ways to stop the gro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Recruiting
This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Quizartinib may stop the growth of tumor cells by blocking some of the enzymes needed... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
Recruiting
This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/01/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Omalizumab Weight-Based Dosing Efficacy Trial
Recruiting
This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.
Gender:
ALL
Ages:
Between 1 year and 55 years
Trial Updated:
05/30/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Allergies, Food Allergy
Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing
Recruiting
This single-arm, multi-center, prospective study will assess the coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and determinants thereof (transit time, Pa, Pd) in patients before and after intracoronary nitroglycerine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Baylor Scott & White The Heart Hospital - Plano, Plano, Texas
Conditions: ANOCA - Angina With Non-obstructive Coronary Arteries, INOCA (Ischemia With Non Obstructive Coronary Artery Disease)
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
Recruiting
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes. This can lead to an enlarged spleen and lymph nodes. Current treatments for ALPS can have many adverse effects. Better treatments for ALPS are needed. Objective: To test a study drug (soquelitinib) in people with ALPS. Eligibility: People aged 16 years and older with ALPS. Design:... Read More
Gender:
ALL
Ages:
Between 16 years and 120 years
Trial Updated:
05/30/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Autoimmune Lymphoproliferative Syndrome
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Austin, Texas
Conditions: Chronic Granulomatous Disease (CGD)
Falcon Real World Evidence Registry
Recruiting
This is a multi-site registry of patients receiving the Exact Sciences Multicancer Early Detection (MCED) test.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/30/2025
Locations: Baylor Scott & White Health, Dallas, Texas
Conditions: Cancer
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: The University of Texas MD Anderson Cancer Center /ID# 264020, Houston, Texas
Conditions: Breast Reconstruction